Results 221 to 230 of about 660,366 (297)
An AMP (P 3‐3R‐8I) based on natural peptides, which can target bacterial cell membranes, was precisely constructed via amino acid mutation. P 3‐3R‐8I exhibits antibacterial capability which could be attributed to the ability of P 3‐3R‐8I to quickly penetrate bacterial cell membranes and then to bind to bacterial DNA.
Jiaqi Huang +11 more
wiley +1 more source
Systematic Identification of the Serine Protease Family (StSPs) and Functional Characterization of the Secretory Protein StSP8-4 for Pathogenicity in <i>Setosphaeria turcica</i>. [PDF]
Zhou Q +8 more
europepmc +1 more source
Hypertrophic scar formation is driven by excessive mitochondrial fission in wound macrophages, which we discover is governed by a novel AURKB‐DRP1(Ser616) axis. The study develops a targeted therapy using cRGD‐decorated extracellular vesicles to deliver the natural compound Asiaticoside specifically to macrophages.
Luyu Li +8 more
wiley +1 more source
Non-targeted metabolomics reveals liver metabolome changes in broiler chickens fed diets supplemented with fermented brewer's grain. [PDF]
Gong Z, Wang Q, Li Y.
europepmc +1 more source
Ng et al. show that the BCR::ABL1 kinase that drives the lymphoid leukemia Ph+B‐ALL modulates enhancer function by coopting signaling‐inducible transcription factors such as MYC, STAT5, and ETV5. BCR::ABL1 thereby promotes the transcriptional program driving and defining this leukemia and renders Ph+B‐ALL cells hypersensitive to enhancer‐inhibiting ...
Han Leng Ng +19 more
wiley +1 more source
S9 protease WprP<sub>2</sub> catalyzes uniform cleavage on the precursor peptide in RiPP biosynthesis. [PDF]
Haedar JR +4 more
europepmc +1 more source
This review comprehensively overviews attenuated bacteria‐based tumor therapy, highlighting key methodologies and recent progress. It examines strategies for enhancing safety, stabilizing efficacy, optimizing manufacturing, and navigating regulatory pathways.
Yucheng Liu +8 more
wiley +1 more source

